Acquisition to Expand Thomson Scientific's Market-leading Portfolio of
Chemistry and Drug Discovery Information Solutions
STAMFORD, Conn., Sept. 27 /CNW/ -- The Thomson Corporation (NYSE: TOC;
TSX: TOC), a leading provider of information solutions to business and
professional customers worldwide, today announced that it has acquired Prous
Science, a global leader in the provision of life sciences information
solutions. Prous Science will become part of Thomson Scientific. Financial
terms of the transaction were not disclosed.
Scientists worldwide rely on Prous Science information solutions to
enhance knowledge-based drug discovery and development. Its well-known Prous
Science Integrity(R) portal provides access to more than 265,000 compounds
with demonstrated biological activity and close to 100,000 patent family
records. Prous Science has worked closely with its customers and partners to
develop this highly differentiated information offering tailored to the needs
of end user scientists.
In addition, Prous Science has developed strong relationships with key
global medical associations and Centers of Excellence to maximize the reach of
medical knowledge to specialists worldwide.
"Prous Science has built a strong global brand on its flagship solutions
which have been built by scientists for scientists," said Vin Caraher,
President and CEO, Thomson Scientific. "This acquisition really complements
our Pharma & Biotechnology workflow solution offerings. We look forward to
working closely with the Prous Science management team to maximize synergies
and add value for our customers."
"Today's announcement signals an excellent opportunity to accelerate our
product development and innovation plan in the drug discovery space. By
combining the financial strength, creativity and technology of Thomson with
Prous Science, we will further drive innovations that help scientists find
better solutions to their specific problems while fostering the emergence of
new ideas," said Dr. J.R. Prous, President and CEO, Prous Science.
Headquartered in Barcelona, Spain, where the company's operations will
remain, Prous Science serves key strategic geographic areas including Europe,
Japan, North America and Latin America. Founded in 1958 by current President
and CEO Dr. J.R. Prous, the company has more than 180 employees. Prous Science
management and employees will become part of the Pharmaceutical/Chemical
business unit within Thomson Scientific.
"Thomson Scientific, through its core products, including Thomson Pharma,
IDDB, Derwent World Patents Index and Web of Science, has particular strengths
in patent, business intelligence and investigational drug information," said
Jon Brett-Harris, Executive Vice President of Pharma/Chem Markets, Thomson
Scientific. "The Prous Integrity platform complements our portfolio offering
by providing unparalleled drug discovery content and unique analytic
functionality for chemists and biologists."
"Our strong background in the life sciences coupled with Thomson
Scientific's expertise in intellectual property and competitive intelligence
equal a powerful value proposition for customers of both companies," added Dr.
Josep Prous Jr., Executive Vice President, Prous Science.
The Thomson Corporation
The Thomson Corporation ( http://www.thomson.com ) is a global leader in
providing essential electronic workflow solutions to business and professional
customers. With operational headquarters in Stamford, Conn., Thomson provides
value-added information, software tools and applications to professionals in
the fields of law, tax, accounting, financial services, scientific research
and healthcare. The Corporation's common shares are listed on the New York and
Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Thomson Scientific is a business of The Thomson Corporation. Its
information solutions assist professionals at every stage of research and
development-from discovery to analysis to product development and
distribution. Thomson Scientific information solutions can be found at
About Prous Science
For more than 40 years, Prous Science has been a trusted source of
information on which science depends to discover safer and more effective
medicines. The company's products have evolved through the years from print
journals to sophisticated electronic products incorporating the latest
advances in IT. The company has complemented its Drug discovery solutions with
a series of key partnerships to widen the dissemination of Medical Education
worldwide by fostering relationships with key Medical Institutions and centers
of excellence worldwide. For more information about Prous Science, visit
This news release includes forward-looking statements which are based on
certain assumptions and reflect The Thomson Corporation's current
expectations. All forward-looking statements in this news release are subject
to a number of risks and uncertainties that could cause actual results or
events to differ materially from current expectations. Some of the factors
that could cause actual results to differ materially from current expectations
include risks related to Thomson Scientific's ability to successfully
integrate Prous Science, and actions of Thomson Scientific's competitors.
Additional factors are discussed in the Corporation's materials filed with the
securities regulatory authorities in Canada and the United States from time to
time, including the Corporation's latest annual information form, which is
contained in its most recently filed annual report on Form 40-F. The
Corporation disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, other than as required by law.
For further information:
For further information: Media, Allison Hagan, +1-215-823-1881,
firstname.lastname@example.org, or Investors, Frank J. Golden, Vice President,
Investor Relations, +1-203-539-8470, email@example.com, both of
Thomson Scientific Web Site: http://www.thomson.com